Ignite Creation Date:
2024-05-05 @ 10:48 PM
Last Modification Date:
2024-10-26 @ 10:24 AM
Study NCT ID:
NCT01193959
Status:
COMPLETED
Last Update Posted:
2022-09-10
First Post:
2010-08-26
Brief Title:
Pemetrexed in Advanced Non-small Cell Lung Cancer
Sponsor:
Armando Santoro MD
Organization:
Istituto Clinico Humanitas
Study Overview
Official Title:
Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the second line setting in a large cohort of advanced non-small cell lung cancer NSCLC patients The following biomarkers will be investigated with either immunohistochemistry fluorescence in situ hybridization or genotyping thymidylate synthase TS dihydrofolate reductase DHFR glycinamide ribonucleotide formyl transferase GARFT aminoimidazole carboxamide ribonucleotide formyltransferase ATICAICARFT epidermal growth factor receptor EGFR Kirsten rat sarcoma 2 viral oncogene homolog KRAS v-myc myelocytomatosis viral oncogene homolog MYC and phosphoinositide-3-kinase catalytic alpha polypeptide PIK3CA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None